Welcome!

News Feed Item

Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014

LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/703975/Coronary-Arteriosclerosis-Global-Clinical-Trials-Review-H2-2014.html

Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014" provides data on the Coronary Arteriosclerosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Coronary Arteriosclerosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Coronary Arteriosclerosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Coronary Arteriosclerosis 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Coronary Arteriosclerosis 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Coronary Arteriosclerosis Therapeutics Clinical Trials 29
Prominent Drugs 30
Clinical Trial Profiles 31
Clinical Trial Overview of Top Companies 31
Pfizer Inc. 31
Clinical Trial Overview of Pfizer Inc. 31
Merck & Co., Inc. 32
Clinical Trial Overview of Merck & Co., Inc. 32
Eli Lilly and Company 33
Clinical Trial Overview of Eli Lilly and Company 33
Cytori Therapeutics, Inc. 34
Clinical Trial Overview of Cytori Therapeutics, Inc. 34
C. H. Boehringer Sohn AG & Co. KG 35
Clinical Trial Overview of C. H. Boehringer Sohn AG & Co. KG 35
AstraZeneca PLC 36
Clinical Trial Overview of AstraZeneca PLC 36
MDDX LLC 37
Clinical Trial Overview of MDDX LLC 37
Innovaderm Research Inc. 38
Clinical Trial Overview of Innovaderm Research Inc. 38
CardioVascular BioTherapeutics, Inc. 39
Clinical Trial Overview of CardioVascular BioTherapeutics, Inc. 39
Avant Immunotherapeutics, Inc 40
Clinical Trial Overview of Avant Immunotherapeutics, Inc 40
Clinical Trial Overview of Top Institutes / Government 41
National Heart, Lung, and Blood Institute 41
Clinical Trial Overview of National Heart, Lung, and Blood Institute 41
Providence VA Medical Center 42
Clinical Trial Overview of Providence VA Medical Center 42
National Taiwan University Hospital 43
Clinical Trial Overview of National Taiwan University Hospital 43
Seoul National University Hospital 44
Clinical Trial Overview of Seoul National University Hospital 44
Rigshospitalet 45
Clinical Trial Overview of Rigshospitalet 45
University of Ottawa Heart Institute 46
Clinical Trial Overview of University of Ottawa Heart Institute 46
University of California, San Diego 47
Clinical Trial Overview of University of California, San Diego 47
University of Minnesota 48
Clinical Trial Overview of University of Minnesota 48
Massachusetts General Hospital 49
Clinical Trial Overview of Massachusetts General Hospital 49
U.S. Department of Veterans Affairs 50
Clinical Trial Overview of U.S. Department of Veterans Affairs 50
Five Key Clinical Profiles 51
Appendix 81
Abbreviations 81
Definitions 81
Research Methodology 82
Secondary Research 82
About GlobalData 83
Contact Us 83
Disclaimer 83
Source 83

List of Tables
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Region, 2014* 7
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Coronary Arteriosclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Coronary Arteriosclerosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Coronary Arteriosclerosis Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Coronary Arteriosclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Coronary Arteriosclerosis Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 15
Coronary Arteriosclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Coronary Arteriosclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 18
Coronary Arteriosclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Coronary Arteriosclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Coronary Arteriosclerosis Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Coronary Arteriosclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 31
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 32
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 33
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Cytori Therapeutics, Inc., 2014* 34
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by C. H. Boehringer Sohn AG & Co. KG, 2014* 35
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 36
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by MDDX LLC, 2014* 37
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Innovaderm Research Inc., 2014* 38
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by CardioVascular BioTherapeutics, Inc., 2014* 39
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Avant Immunotherapeutics, Inc, 2014* 40
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Heart, Lung, and Blood Institute, 2014* 41
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Providence VA Medical Center, 2014* 42
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Taiwan University Hospital, 2014* 43
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Seoul National University Hospital, 2014* 44
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Rigshospitalet, 2014* 45
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Ottawa Heart Institute, 2014* 46
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Diego, 2014* 47
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Minnesota, 2014* 48
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014* 49
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by U.S. Department of Veterans Affairs, 2014* 50

List of Figures
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Coronary Arteriosclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Coronary Arteriosclerosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Coronary Arteriosclerosis Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Coronary Arteriosclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 15
Coronary Arteriosclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Coronary Arteriosclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 18
Coronary Arteriosclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Coronary Arteriosclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Coronary Arteriosclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
GlobalData Methodology 82

Read the full report:
Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/703975/Coronary-Arteriosclerosis-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The buzz continues for cloud, data analytics and the Internet of Things (IoT) and their collective impact across all industries. But a new conversation is emerging - how do companies use industry disruption and technology enablers to lead in markets undergoing change, uncertainty and ambiguity? Organizations of all sizes need to evolve and transform, often under massive pressure, as industry lines blur and merge and traditional business models are assaulted and turned upside down. In this new da...
Unsecured IoT devices were used to launch crippling DDOS attacks in October 2016, targeting services such as Twitter, Spotify, and GitHub. Subsequent testimony to Congress about potential attacks on office buildings, schools, and hospitals raised the possibility for the IoT to harm and even kill people. What should be done? Does the government need to intervene? This panel at @ThingExpo New York brings together leading IoT and security experts to discuss this very serious topic.
SYS-CON Events announced today that Hitrons Solutions will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Hitrons Solutions Inc. is distributor in the North American market for unique products and services of small and medium-size businesses, including cloud services and solutions, SEO marketing platforms, and mobile applications.
It is one thing to build single industrial IoT applications, but what will it take to build the Smart Cities and truly society changing applications of the future? The technology won’t be the problem, it will be the number of parties that need to work together and be aligned in their motivation to succeed. In his Day 2 Keynote at @ThingsExpo, Henrik Kenani Dahlgren, Portfolio Marketing Manager at Ericsson, discussed how to plan to cooperate, partner, and form lasting all-star teams to change the...
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busine...
All clouds are not equal. To succeed in a DevOps context, organizations should plan to develop/deploy apps across a choice of on-premise and public clouds simultaneously depending on the business needs. This is where the concept of the Lean Cloud comes in - resting on the idea that you often need to relocate your app modules over their life cycles for both innovation and operational efficiency in the cloud. In his session at @DevOpsSummit at19th Cloud Expo, Valentin (Val) Bercovici, CTO of Soli...
“We're a global managed hosting provider. Our core customer set is a U.S.-based customer that is looking to go global,” explained Adam Rogers, Managing Director at ANEXIA, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
The buzz continues for cloud, data analytics and the Internet of Things (IoT) and their collective impact across all industries. But a new conversation is emerging - how do companies use industry disruption and technology enablers to lead in markets undergoing change, uncertainty and ambiguity? Organizations of all sizes need to evolve and transform, often under massive pressure, as industry lines blur and merge and traditional business models are assaulted and turned upside down. In this new da...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his general session at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore...
WebRTC services have already permeated corporate communications in the form of videoconferencing solutions. However, WebRTC has the potential of going beyond and catalyzing a new class of services providing more than calls with capabilities such as mass-scale real-time media broadcasting, enriched and augmented video, person-to-machine and machine-to-machine communications. In his session at @ThingsExpo, Luis Lopez, CEO of Kurento, introduced the technologies required for implementing these idea...
In an era of historic innovation fueled by unprecedented access to data and technology, the low cost and risk of entering new markets has leveled the playing field for business. Today, any ambitious innovator can easily introduce a new application or product that can reinvent business models and transform the client experience. In their Day 2 Keynote at 19th Cloud Expo, Mercer Rowe, IBM Vice President of Strategic Alliances, and Raejeanne Skillern, Intel Vice President of Data Center Group and G...
Financial Technology has become a topic of intense interest throughout the cloud developer and enterprise IT communities. Accordingly, attendees at the upcoming 20th Cloud Expo at the Javits Center in New York, June 6-8, 2017, will find fresh new content in a new track called FinTech.
@GonzalezCarmen has been ranked the Number One Influencer and @ThingsExpo has been named the Number One Brand in the “M2M 2016: Top 100 Influencers and Brands” by Onalytica. Onalytica analyzed tweets over the last 6 months mentioning the keywords M2M OR “Machine to Machine.” They then identified the top 100 most influential brands and individuals leading the discussion on Twitter.
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.
Manufacturers are embracing the Industrial Internet the same way consumers are leveraging Fitbits – to improve overall health and wellness. Both can provide consistent measurement, visibility, and suggest performance improvements customized to help reach goals. Fitbit users can view real-time data and make adjustments to increase their activity. In his session at @ThingsExpo, Mark Bernardo Professional Services Leader, Americas, at GE Digital, discussed how leveraging the Industrial Internet and...